TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05145010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Study: NCT06637644

Intervention type: DEVICE
Intervention: Right-sided ventricular assist device
Description: Percutaneous device for right heart support
Study: NCT06639659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block
Description: patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Anesthesia (control group)
Description: patients will be operated under general anesthesia including routine protocol for these cases
Study: NCT06207435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation
Description: Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
Study: NCT06471257

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/Albuterol metered dose inhaler, MDI
Description: Combination Product (Drug + Device)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered dose inhaler, MDI
Description: Combination Product (Drug + Device)
Study: NCT06645444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant placement with customized PEEK healing abutment
Description: * an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with customized PEEK healing abutment
Description: * an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery.
Study: NCT06644534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: (cysteamine-pantetheine disulfide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pearlitol® 100 SD (mannitol)
Study: NCT05595239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(TPE+CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood purification(HP+CVVH)
Description: After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
Study: NCT05731245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
Description: Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
Study: NCT05749926

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
Description: A single administration of COVID-19 vaccine will be performed at D0, depending on randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VidPrevtyn® Beta vaccine (Sanofi/GSK)
Description: A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
Study: NCT05279612

Intervention type: RADIATION
Intervention: Short-term neoadjuvant chemoradiotherapy
Description: Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
Study: NCT04749706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training alone
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training alone
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training + protein intake
Description: The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine
Study: NCT05960552

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The PReTEE group
Description: Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The conventional TEE group
Description: Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
Study: NCT06557902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 10.5 mg capsule
Description: Lumateperone 10.5 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 21 mg capsule
Description: Lumateperone 21 mg capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 5 mg ODT
Description: Lumateperone 5 mg ODT, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 10.5 mg ODT
Description: Lumateperone 10.5 mg ODT, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 15.5 mg ODT
Description: Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 21 mg ODT
Description: Lumateperone 21 mg ODT, oral administration
Study: NCT06410599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
Study: NCT06281834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
Study: NCT06410599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
Study: NCT05617196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual PREHAB
Description: The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
Study: NCT05197842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Orally administered
Study: NCT06042491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Description: The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
Study: NCT06410599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBASP
Description: In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBASP
Description: In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
Study: NCT05336526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
Description: Bilateral brest augmentation in primary intention
Study: NCT05092815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po
Study: NCT04784494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Theapy (MagPro XP MST)
Description: MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study: NCT06410599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
Study: NCT03914482

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
Study: NCT05530798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definity Perflutren Lipid Microsphere Ultrasound Contrast
Description: 1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had.
Study: NCT05878093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: nasal spray (suspension)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: nasal spray (suspension)
Study: NCT06603844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB-601 monoclonal antibody
Description: CRB-601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD(L)-1 used as per label

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Immune-priming single lesion SBRT
Description: single-lesion immune-priming SBRt

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Immune-priming single lesion SBRT
Description: single-lesion immune-priming SBRt

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Immune-priming single lesion SBRT
Description: single-lesion immune-priming SBRt

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Immune-priming single lesion SBRT
Description: single-lesion immune-priming SBRt
Study: NCT06691100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).